StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals Equity incentive plans by Year

Equity incentive plans — Shares available for future grant (M shares) (M)

Vertex Pharmaceuticals Equity incentive plans: 10.9M in FY2025, down 20.8% from a year earlier.

Latest, FY2025
10.9
Period ended Dec 31, 2025
Change on a year earlier
-20.8%
13.8 in FY2024
History
11 years
Since FY2015
Sources
11
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-13) ↗

Reported in Form 10-K Note (Stock-based Compensation).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedEquity incentive plans — Shares available for future grant (M shares) (M)Year on yearSource
FY2025Dec 31, 202510.9-20.8%Form 10-K (filed 2026-02-13) ↗
FY2024Dec 31, 202413.8-16.7%Form 10-K (filed 2025-02-13) ↗
FY2023Dec 31, 202316.5-16.2%Form 10-K (filed 2024-02-15) ↗
FY2022Dec 31, 202219.7+106.1%Form 10-K (filed 2023-02-10) ↗
FY2021Dec 31, 20219.56-28.6%Form 10-K (filed 2022-02-09) ↗
FY2020Dec 31, 202013.4-15.2%Form 10-K (filed 2021-02-11) ↗
FY2019Dec 31, 201915.8+7.1%Form 10-K (filed 2020-02-13) ↗
FY2018Dec 31, 201814.7+29.0%Form 10-K (filed 2019-02-13) ↗
FY2017Dec 31, 201711.4+24.5%Form 10-K (filed 2018-02-15) ↗
FY2016Dec 31, 20169.18-35.0%Form 10-K (filed 2017-02-23) ↗
FY2015Dec 31, 201514.1–Form 10-K (filed 2016-02-16) ↗

Cite this data

StockData. (2026). Vertex Pharmaceuticals Equity incentive plans (M), annual FY2015–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/plan-avail-sh

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.